Aerie Pharmaceuticals Logo

Investors

We began with a vision, and now we’ve grown into an ophthalmic pharmaceutical company focused on discovering, developing and commercializing first-in-class therapies for treating open-angle glaucoma and other diseases of the eye.

LEADERSHIP TEAM

Meet the eye care VISIONaerieS™ building the next major ophthalmic pharmaceutical company.

MORE

STOCK INFORMATION

NASDAQ: AERI
$65.75
Aug 14, 2018 4:00 PM EDT

MORE

REPORTS AND FILINGS

Review the latest annual report, quarterly reports, and other SEC filings.

MORE